Drug research: marketing before evidence, sales before safety.
Klemperer
David
D
D014150:Antipsychotic Agents / Q000191:economics / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000191:economics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000191:economics* / Q000941:ethics*; D016265:Conflict of Interest / Q000191:economics*; D004345:Drug Industry / Q000191:economics / Q000941:ethics*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000191:economics; D004994:Ethics, Pharmacy; D019317:Evidence-Based Medicine / Q000191:economics / Q000941:ethics; D005607:Fraud / Q000191:economics / Q000941:ethics; D005858:Germany; D006801:Humans; D033181:Information Dissemination; D040541:Marketing / Q000941:ethics*; D000077152:Olanzapine; D017594:Publication Bias; D012109:Research Support as Topic / Q000191:economics* / Q000941:ethics*; D018967:Risperidone / Q000191:economics / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D018967:Risperidone; D000077152:Olanzapine
JAMA. 2003 Jan 22-29;289(4):454-65
12533125
Am J Psychiatry. 2006 Feb;163(2):185-94
16449469
Dtsch Arztebl Int. 2010 Apr;107(16):279-85
20467553
JAMA. 2010 Mar 24;303(12):1194-5
20332408
JAMA. 2008 Apr 16;299(15):1813-7
18413875
Ann Fam Med. 2009 Nov-Dec;7(6):542-6
19901314
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2009 Apr;52(4):463-8
19308331
N Engl J Med. 2004 Oct 21;351(17):1707-9
15470193